DoubleLine ETF Adviser’s Moderna MRNA Stock Holding History

DoubleLine ETF Adviser’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Sell	3,760 -466	-11%	-$24.1K	0.11%	153
2026 Q1	$215K	Buy	+4,226	New	+$197K	0.08%	167

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

DoubleLine ETF Adviser's MRNA Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its Moderna (MRNA) stake by 11% in Q2 2026, selling an estimated $24.1K and leaving 3,760 shares worth $263K. The position accounts for 0.11% of the portfolio, ranked #153.

DoubleLine ETF Adviser first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

DoubleLine ETF Adviser held 3,760 shares of Moderna worth $263K as of Q2 2026.
DoubleLine ETF Adviser sold 466 Moderna shares in Q2 2026, an estimated $24.1K.
Moderna made up 0.11% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #153 holding.
DoubleLine ETF Adviser first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.